The 10x Genomics, Inc. company was founded in 2005.. (Nasdaq: TXG), a global leader in the field of single cells and spatial biology, announced today that a jury in the United States has ruled that. In the patent infringement suit that 10x Genomics filed against the GeoMx products sold by NanoString Technologies, Inc. in the District Court for the District of Delaware, a unanimous verdict has been reached in favor of 10x Genomics.. (NSTG - Nasdaq: NSTG). As a result of the jury awarding NanoString over $31 million in damages for the GeoMx Digital Spatial Profiler and the associated instruments, reagents, and services for RNA and protein detection, all seven asserted patents which were owned by Prognosys and exclusively licensed to 10x Genomics were willfully infringed by NanoString.
As a result of the jury awarding NanoString over $31 million in damages for the GeoMx Digital Spatial Profiler and the associated instruments, reagents, and services for RNA and protein detection, all seven asserted patents which were owned by Prognosys and exclusively licensed to 10x Genomics were willfully infringed by NanoString.
As a result of the jury's decision, GeoMx has been awarded over $31 million in damages for the sale of infringing GeoMx products between May 6, 2021 and October 13, 2023.. During the post-trial proceedings, 10x intends to request the following: (a) ongoing royalties in compensation for NanoString's willful infringement of GeoMx after October 13, 2023; (b) treble damages and attorney's fees for NanoString's willful infringement; (c) a permanent injunction barring the manufacture, use, sale, and offer for sale of GeoMx products in the United States; and (d) interest both before and after the judgment
During the post-trial proceedings, 10x intends to request the following: (a) ongoing royalties in compensation for NanoString's willful infringement of GeoMx after October 13, 2023; (b) treble damages and attorney's fees for NanoString's willful infringement; (c) a permanent injunction barring the manufacture, use, sale, and offer for sale of GeoMx products in the United States; and (d) interest both before and after the judgment
In the last six months, three separate courts have found that NanoString's CosMx and GeoMx products infringe nine patents that belong to 10x Genomics and were established as infringing," said Eric Whitaker, Chief Legal Officer at 10x Genomics.. As a matter of fact, NanoString should abandon the charade that it is 'confident' that it does not infringe upon the 10x patents and that they are invalid at some point in the future. To advance our mission and continue to innovate and push science forward, it is essential that 10x protect our patents from those who wrongfully and willfully use them in an attempt to harm our mission and the progress of science.. It is with great pleasure that we acknowledge and appreciate the jury's careful consideration of the extensive evidence presented in this case and their diligence in recognizing 10x's decade-long investment in innovation over the last decade
It is with great pleasure that we acknowledge and appreciate the jury's careful consideration of the extensive evidence presented in this case and their diligence in recognizing 10x's decade-long investment in innovation over the last decade
In addition to Mark Chee, the sole inventor of the patents, as well as NanoString's CEO Brad Gray and CSO Joe Beechem, the jury heard testimony from the sole inventor of the patents, Illumina co-founder Mark Chee.. As a result of hearing all of the evidence presented to the jury, the jury ruled that all seven of the patents asserted by 10x were infringed by NanoString, that all seven patents asserted by 10x were valid, that NanoString willfully infringed on all seven patents, and that 10x was entitled to monetary damages for the infringements of all seven patents.. In order to find that a patent was willfully infringed, the jury had to find that NanoString acted in reckless disregard of 10x's rights, accompanied by evidence indicating that NanoString acted maliciously, deliberately, or in bad faith.
In order to find that a patent was willfully infringed, the jury had to find that NanoString acted in reckless disregard of 10x's rights, accompanied by evidence indicating that NanoString acted maliciously, deliberately, or in bad faith.
Among the patents asserted in Case No. 21-cv-653-MFK are (a) the U.S. Patent No. 10,472,669, (b) the U.S. Patent No. 10,961,566, (c) the U.S. Patent No. 10,983,113, (d) the U.S. Patent No. 10,996,219, (e) the U.S. Patent No. 11,001,878 and (f) the U.S. Patent No. 11,008,607 and (g) the U.S.
In the last six months, NanoString has been convicted of infringing on more than ten patents for the third time. A few months ago, NanoString was ruled to be infringing on 10x Genomics patents by the European Unified Patent Court (the "UPC") as well as the Munich Regional Court. NanoString's infringing CosMx Spatial Molecular Imager instruments and CosMx reagents for RNA detection were injunched by the Munich Regional Court.
Litigation Related to NanoString10x has filed a separate lawsuit in the United States against NanoString. The District Court for the District of Delaware has filed a complaint alleging that NanoString's CosMx Spatial Molecular Imager and associated instruments, reagents and services are infringing multiple patents held by the district court. There are two patents asserted in the second U.S. patent application. A number of plaintiffs are suing NanoString, including: (a). No. of the patent:. (a) 10,227,639; (b) U.S.. No. of the patent. 11,021,737; (c) United States. No. of the patent. There are 11,293,051; (d) United States. There is a patent number for this invention. A total of 11,293,052; (e) United States. There is a patent number for this invention. A total of 11,293,054 and (f) United States. No. of the patent. 11,542,554. In September 2024, a trial is scheduled to take place
In September 2024, a trial is scheduled to take place
10x Genomics is a life science technology company that builds products to accelerate the mastery of biology and advance human health through the advancement of science. With our integrated solutions, we offer instruments, consumables, and software for single cell and spatial biology, which enable academic and translational researchers as well as biopharmaceutical companies to understand biological systems at a level of resolution and scale that matches the complexity of biology itself.. It is our products that are behind breakthroughs in the fields of oncology, immunology, neuroscience, and more, fueling powerful discoveries that are transforming how we understand health and disease all around the world.. You can learn more about 10xgenomics by visiting their website.If you would like to connect with us, please email us or connect on LinkedIn or X (Twitter).
If you would like to connect with us, please email us or connect on LinkedIn or X (Twitter).
As a result of the Private Securities Litigation Reform Act of 1995 as provided in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, this press release contains forward-looking statements that are subject to the protections provided by those sections, namely the "safe harbor" created by those provisions.. It is possible that all statements, other than statements of historical fact, may be considered forward-looking statements. As a general rule, forward-looking statements can be identified by the use of such forward-looking terminology as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," "would," "likely," "seek" or "continue," or the negatives of these terms or variations of them or similar terminology or the absence of any of these words does not mean that a statement is not forward-looking.. As part of these forward-looking statements, 10x Genomics, Inc. makes the following statements:.A description of the client's expectations regarding litigation and remedies, as well as the possible outcomes of litigation. The statements in this press release are based on management's current expectations, forecasts, beliefs, assumptions, and information currently available to management, and actual outcomes and results may differ materially from those in these statements due to a variety of factors.. A list of the material risks and uncertainties that could affect 10x Genomics, Inc..'s financial and operating results and causing actual results to differ materially from those indicated by the forward-looking statements made in this press release. The following factors are discussed in the documents 10x Genomics, Inc. under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" as well as elsewhere.. From time to time, the company files with the Securities and Exchange Commission.Despite the fact that 10x Genomics, Inc.. In spite of the fact that the company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that these expectations will prove to be correct, nor can it guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur.. Our ability to obtain, maintain and protect our intellectual property rights will play a significant role in our success, as these forward-looking statements do not reflect this. Our ability to develop, manufacture and commercialize our products or technologies may be hindered by intellectual property litigation, which could be costly, time-consuming, and unsuccessful. In addition to the unpredictable outcome of litigation, there may be changes in our litigation strategy.. This press release contains forward-looking statements based on information that 10x Genomics, Inc. has access to as of the date of this press release.. In accordance with the terms of this agreement, 10x Genomics, Inc.. Except to the extent required by law, we disclaim any obligation to update any forward-looking statements made by us to reflect any change in our expectations or to reflect any change in events, conditions, or circumstances on which any such statement is based.. We caution you that these forward-looking statements should not be construed as representations of 10x Genomics, Inc..Views of the company as of any date following the date on which this press release was issued
Views of the company as of any date following the date on which this press release was issued
Among the ways in which Tenx Genomics discloses material non-public information, it utilizes filings with the Securities and Exchange Commission, our website (10xgenomics.com), press releases, public conference calls, public webcasts and social media accounts to comply with Regulation FD requirements as well as to disclose material non-public information.
Contact Information Investors: [email protected] Media: [email protected]
The source of this information is 10x Genomics, Inc.
Owkin and 10x Genomics, Inc. (Nasdaq: TXG), have announced that they have entered into an agreement to add 10x Genomics' spatial omics and single-cell genomics capabilities to Owkin...
This morning, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced its financial results for the third quarter ended September 30, 2008..
Take advantage of PRN's weekly email newsletter to be the first to know about PRN's top stories and curated news.

Source prnewswire